HTG Molecular

For the three months ended March 31, the firm said that preliminary revenues for Q1 are expected to be $1.4 million compared with $3.2 million a year ago.

For the year ended Dec. 31, 2020, the firm reported revenues of $8.5 million compared to $19.2 million in 2019, beating the Wall Street estimate of $8.3 million. 

The firm reported preliminary revenues of $8.5 million for full-year 2020, which would beat the consensus Wall Street estimate of $8.0 million.

The company stock will now trade on a split-adjusted basis on the Nasdaq after reducing its number of shares from 200 million to 26.7 million. 

For the three months ended Sept. 30, the firm reported revenues of $1.8 million compared to $5.4 million in the same period the year before.

Carlsbad, California-based BioSpyder said that HTG has repeatedly and baselessly accused it of infringing HTG's patent for quantitative nuclease protection assay and sequencing improvements.

For the three months ended June 30, the Tucson, Arizona-based firm's revenues fell to $2.0 million from $5.8 million in the same period the year before.

HTG will work directly with biopharma customers to build companion diagnostic development programs, with potential tests developed using either a Thermo Fisher Scientific or Illumina platform.

The firm used the new loan to pay off an older $7.0 million loan and a $3.0 million promissory note held by Qiagen North American Holdings.